One vaccine dose enough for COVID-19 survivors

Two mRNA vaccines against COVID-19 have proven safe and effective in clinical trials, as well as in the millions of people who have been vaccinated so far. But how prior SARS-CoV-2 infection affects vaccine response, and how long that response lasts, are still uncertain. Now, a new study in ACS…

Which COVID-19 Vaccine Is The Most Popular?

On December 14, 2020, Sandra Lindsay, a critical care nurse, became the first person to receive a COVID-19 vaccine in the United States, outside of clinical trials. As reported by The Washington Post, the vaccine was developed in record time and was first given to frontline healthcare workers, in hopes…

In Africa, vaccine hesitancy adds to slow rollout of doses

Some Africans are hesitating to get COVID-19 vaccines amid concerns about their safety, alarming public health officials as some countries start to destroy thousands of doses that expired before use. Malawi and South Sudan in recent days have said they will destroy some of their doses, a concerning development on…

Few SARS-CoV-2 vaccine breakthrough infections reported at SNFs

(HealthDay)—Few cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported at skilled nursing facilities (SNFs) among those with at least 14 days since receipt of the second dose of a two-dose COVID-19 vaccine series, according to research published in the April 21 early-release issue of the…

J&J ‘very confident’ in vaccine, eyes quick resolution

Johnson & Johnson remains “very confident” in its COVID-19 vaccine and hopeful for a quick resolution from regulators over its status, a top executive said Tuesday. “We remain very confident and very hopeful that the benefit-risk profile will play out,” J&J Chief Financial Officer Joseph Wolk told CNBC. The comments…